Literature DB >> 18022694

Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system.

Mutsumi Takahata1, Miyuki Bohgaki, Tadasuke Tsukiyama, Takeshi Kondo, Masahiro Asaka, Shigetsugu Hatakeyama.   

Abstract

The 52-kDa form of SSA/Ro protein (Ro52) is one of autoantigens associated with autoimmune disorders such as systemic lupus erythematosus and Sjögren's syndrome. Anti-SSA/Ro antibodies, the biological function of which remains unknown, are frequently found in the serum of these patients. Recent functional genomic approaches have shown that Ro52/TRIM21 is one of the TRIM family proteins with a RING-finger domain which is closely associated with E3 ubiquitin ligase activity. We found by using yeast-two hybrid screening that Ro52 has an E3 activity in vitro and interacts with human IgG1 heavy chain. We also found that IgG1 heavy chain was modified with polyubiquitination by Ro52 and degraded through the ubiquitin-proteasome system in mammalian cells. Our results also showed that Ro52 interacts with the molecular chaperone p97/VCP, which is thought to function in the endoplasmic reticulum associated degradation (ERAD) system. It is likely that Ro52 plays a role in proteasomal degradation of unfolded IgG1, which is retrogradely transferred from the endoplasmic reticulum to the cytosol. Taken together, our findings suggest that Ro52 plays a significant role in quality control of IgG1 through the ERAD system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022694     DOI: 10.1016/j.molimm.2007.10.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  17 in total

1.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Authors:  Rodger E Tiedemann; Yuan Xao Zhu; Jessica Schmidt; Chang Xin Shi; Chris Sereduk; Hongwei Yin; Spyro Mousses; A Keith Stewart
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

2.  Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts.

Authors:  Ryusuke Yoshimi; Tsung-Hsien Chang; Hongsheng Wang; Toru Atsumi; Herbert C Morse; Keiko Ozato
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

3.  Is there an association between Ro52/TRIM21 antibodies and rheumatoid factor in systemic sclerosis?

Authors:  Sonal Mehra; Marie Hudson; Michael Mahler; Murray Baron; Marvin Fritzler
Journal:  Rheumatol Int       Date:  2013-03-31       Impact factor: 2.631

4.  TRIM32 protein sensitizes cells to tumor necrosis factor (TNFα)-induced apoptosis via its RING domain-dependent E3 ligase activity against X-linked inhibitor of apoptosis (XIAP).

Authors:  Yeung Sook Ryu; Younglang Lee; Keun Woo Lee; Chae Young Hwang; Jin-Soo Maeng; Jeong-Hoon Kim; Yeon-Soo Seo; Kwan-Hee You; Byeongwoon Song; Ki-Sun Kwon
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

5.  Extraordinary antigenicity of the human Ro52 autoantigen.

Authors:  Peter D Burbelo; Kathryn H Ching; Brian L Han; Emily R Bush; Westley H Reeves; Michael J Iadarola
Journal:  Am J Transl Res       Date:  2010-03-15       Impact factor: 4.060

6.  TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved.

Authors:  Anthony H Keeble; Zahra Khan; Alan Forster; Leo C James
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-17       Impact factor: 11.205

7.  Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome.

Authors:  Peter D Burbelo; Hannah P Leahy; Alexandra T Issa; Sandra Groot; James N Baraniuk; Nikolay P Nikolov; Gabor G Illei; Michael J Iadarola
Journal:  Autoimmunity       Date:  2009-09       Impact factor: 2.815

8.  Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.

Authors:  Alfonso Quintás-Cardama; Sean M Post; Luisa M Solis; Shunbin Xiong; Peirong Yang; Nanyue Chen; Ignacio I Wistuba; Ann M Killary; Guillermina Lozano
Journal:  J Pathol       Date:  2014-07-16       Impact factor: 7.996

9.  Rapid induction of autoantibodies during ARDS and septic shock.

Authors:  Peter D Burbelo; Nitin Seam; Sandra Groot; Kathryn H Ching; Brian L Han; G Umberto Meduri; Michael J Iadarola; Anthony F Suffredini
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

10.  Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus.

Authors:  Ryusuke Yoshimi; Yoshiaki Ishigatsubo; Keiko Ozato
Journal:  Int J Rheumatol       Date:  2012-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.